10.51新台幣0.45(4.11%)
2021/02/25更新
績效 / 1月11.9%
3月0.94%
1年
晨星評等-
- 1.現金9.47%
- 2.股票30.87%
- 3.債券0.00%
- 4.其他59.66%
- 1.美國57.72%
- 2.新興亞洲14.91%
- 3.已開發亞洲6.19%
- 4.日本5.54%
- 5.歐洲不包含歐元區2.69%
- 1.健康護理84.40%
- 2.科技2.38%
- 3.周期性消費1.78%
- 1.Halozyme Therapeutics Inc5.46%
- 2.CVS Health Corp3.48%
- 3.Align Technology Inc3.46%
- 4.Natera Inc3.39%
- 5.Sarepta Therapeutics Inc3.20%
- 6.Jiangsu Hengrui Medicine Co Ltd3.06%
- 7.Masimo Corp3.03%
- 8.M3 Inc2.95%
- 9.Hangzhou Tigermed Consulting Co Ltd Class A2.82%
- 10.Staar Surgical Co2.71%
- 1.現金9.47%
- 2.股票30.87%
- 3.債券0.00%
- 4.其他59.66%
- 1.健康護理84.40%
- 2.科技2.38%
- 3.周期性消費1.78%
- 1.美國57.72%
- 2.新興亞洲14.91%
- 3.已開發亞洲6.19%
- 4.日本5.54%
- 5.歐洲不包含歐元區2.69%
- 1.Halozyme Therapeutics Inc5.46%
- 2.CVS Health Corp3.48%
- 3.Align Technology Inc3.46%
- 4.Natera Inc3.39%
- 5.Sarepta Therapeutics Inc3.20%
- 6.Jiangsu Hengrui Medicine Co Ltd3.06%
- 7.Masimo Corp3.03%
- 8.M3 Inc2.95%
- 9.Hangzhou Tigermed Consulting Co Ltd Class A2.82%
- 10.Staar Surgical Co2.71%